Literature DB >> 16401617

Natural history of treated childhood-onset epilepsy: prospective, long-term population-based study.

Matti Sillanpää1, Dieter Schmidt.   

Abstract

It is not well known how often drug resistance, a major clinical problem, occurs early or late in the course of epilepsy and how often epilepsy follows a continuous, remitting or relapsing-remitting pattern. To provide evidence if, in fact, different patterns of evolution of drug resistance and remission exist, a prospective, long-term population-based study of 144 patients followed on the average for 37.0 years (SD 7.1, median 40.0, range 11-42) since their first seizure before the age of 16 years was performed. At the end of follow-up, 67% of 144 patients were in terminal remission, on or off antiepileptic drugs. Early remission, starting within the first year of treatment, was seen in 45 patients (31%). In 23 (16%) of them, first remission continued, uninterrupted by relapse, to terminal remission. Late remission with a mean delay of 9 years was achieved by a further 72 patients (50%), including 46 (32%) patients who achieved terminal remission without any relapse and suggested, together with 23 patients, a remitting course. Following a relapse after early or late remission, 28 (19%) patients achieved terminal remission, suggesting a remitting-relapsing pattern. Altogether 20 patients (14%) did not re-enter remission, indicating a worsening course of epilepsy. Twenty-seven (19%) patients were drug-resistant from the start to the end of follow-up. In conclusion, half the patients with childhood-onset epilepsy will eventually enter terminal remission without relapse and a fifth after relapse. One-third will have a poor long-term outcome in terms of persistent seizures after remission or without any remission ever.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16401617     DOI: 10.1093/brain/awh726

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  77 in total

1.  Seizure treatment in transplant patients.

Authors:  Paul W Shepard; Erik K St Louis
Journal:  Curr Treat Options Neurol       Date:  2012-08       Impact factor: 3.598

2.  Honing in on risk factors for prolonged remission off medication by reducing heterogeneity.

Authors:  Dale C Hesdorffer
Journal:  Epilepsy Curr       Date:  2012-05       Impact factor: 7.500

3.  Intractable epilepsy: relapsing, remitting, or progressive?

Authors:  Susan Herman
Journal:  Epilepsy Curr       Date:  2010-11       Impact factor: 7.500

4.  Predicting the Course of Childhood Epilepsy: More Uncertain Than Ever.

Authors:  Jeffrey Buchhalter
Journal:  Epilepsy Curr       Date:  2015 Sep-Oct       Impact factor: 7.500

5.  Refractory epilepsy: one size does not fit all.

Authors:  Jacqueline A French
Journal:  Epilepsy Curr       Date:  2006 Nov-Dec       Impact factor: 7.500

6.  Long-term outcomes of childhood epilepsy: "the truth is rarely pure and never simple".

Authors:  John W Miller
Journal:  Epilepsy Curr       Date:  2006 Nov-Dec       Impact factor: 7.500

7.  Association of MDR1 gene C3435T polymorphism with childhood intractable epilepsy: a meta-analysis.

Authors:  Guilian Sun; Xue Sun; Limei Guan
Journal:  J Neural Transm (Vienna)       Date:  2014-02-20       Impact factor: 3.575

8.  Hypercalcemia in Children Using the Ketogenic Diet: A Multicenter Study.

Authors:  Colin P Hawkes; Sani M Roy; Bassem Dekelbab; Britney Frazier; Monica Grover; Jaime Haidet; James Listman; Sarianne Madsen; Marian Roan; Celia Rodd; Aviva Sopher; Peter Tebben; Michael A Levine
Journal:  J Clin Endocrinol Metab       Date:  2021-01-23       Impact factor: 5.958

Review 9.  Management of the patient with medically refractory epilepsy.

Authors:  Tiziana Granata; Nicola Marchi; Erin Carlton; Chaitali Ghosh; Jorge Gonzalez-Martinez; Andreas V Alexopoulos; Damir Janigro
Journal:  Expert Rev Neurother       Date:  2009-12       Impact factor: 4.618

10.  Temporal lobe epilepsy exacerbation during pharmacological inhibition of endogenous neurosteroid synthesis.

Authors:  Matteo Pugnaghi; Giulia Monti; Giuseppe Biagini; Stefano Meletti
Journal:  BMJ Case Rep       Date:  2013-02-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.